Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab

Sarcopenia is a muscle loss syndrome known as a risk factor of various carcinomas. The impact of sarcopenia and sarcopenia-related inflammatory/nutritional markers in metastatic urothelial carcinoma (mUC) treated with pembrolizumab was unknown, so this retrospective study of 27 patients was performe...

Full description

Bibliographic Details
Main Authors: Takuto Shimizu, Makito Miyake, Shunta Hori, Kazuki Ichikawa, Chihiro Omori, Yusuke Iemura, Takuya Owari, Yoshitaka Itami, Yasushi Nakai, Satoshi Anai, Atsushi Tomioka, Nobumichi Tanaka, Kiyohide Fujimoto
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Diagnostics
Subjects:
immune checkpoint inhibitor
Pembrolizumab
Sarcopenia
psoas muscle mass index
neutrophil-to-lymphocyte ratio
prognostic nutritional index
Online Access:https://www.mdpi.com/2075-4418/10/5/310

Internet

https://www.mdpi.com/2075-4418/10/5/310

Similar Items